| Achillion Pharmaceuticals is a biopharmaceutical company. Co. is engaged in the discovery and development of small molecule drug therapies for immune system disorders. Co. is advancing orally administered small molecules from its platform that target complement factor D, an essential protein of the alternative pathway. The alternative pathway plays a role in a number of disease conditions, including therapeutic areas of nephrology, hematology, ophthalmology and neurology. Initially Co. is targeting C3 glomerulopathy, and immune complex membranoproliferative glomerulonephritis, two related rare diseases affecting the kidney, and paroxysmal nocturnal hemoglobinuria, a blood disorder. We show 33 historical shares outstanding datapoints in our ACHN shares outstanding history coverage, used to compute ACHN market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACHN market cap history over the course of time is important for investors
interested in comparing ACHN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACHN versus a peer is one thing; comparing
ACHN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACHN can fluctuate over the course of history.
With this page we aim to empower investors researching ACHN by allowing them to research the ACHN market cap history.